Loading data for INVA — first visit, this takes a few seconds.
Innoviva, Inc. (INVA)
NasdaqGS: INVA
· Real-Time Price · USD
20.97
+0.01 (0.05%)
At close: Aug 31, 2026, 8:00 PM
20.77
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Innoviva, Inc. (INVA) Stock Price, Analysis & Data
No data available
| Bid | 15.1 |
| Market Cap | 1.5B |
| Revenue (ttm) | 440M |
| Net Income (ttm) | 357M |
| 0.34 | |
| 4.31 | |
| 4.82 | |
| 9.4 | |
| P/B (ttm) | 1.22 |
| P/S (ttm) | 3.41 |
| Earnings Date | Nov 4, 2026 |
| Ask | 20.98 |
| Volume | 527,008 |
| Avg. Volume (20D) | 790,840 |
| Open | 20.96 |
| Previous Close | 20.96 |
| Day's Range | 20.80 - 21.07 |
| 52-Week Range | 16.52 - 25.15 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | Sep 8, 2015 |
About INVA
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pre...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2004
Employees 159
Stock Exchange NasdaqGS
Ticker Symbol INVA
Website https://www.inva.com
Financial Performance
In 2025, Innoviva's revenue was 411.33M, an increase of 14.67% compared to the previous year's 358.71M. Earnings were 271.17M, an increase of 1,059.22%.
Financial StatementsEarnings Surprise
Innoviva has released their quarterly earnings on Aug 5, 2026:
- Revenue of $119.59M misses estimates by $0, with 19.25% YoY growth.
- EPS of 0.56 exceeds estimates by 0.06, with -27.27% YoY decline.
Innoviva, Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2